​During 2024 patient navigation programs to be piloted in Georgia, Ohio, and Oregon.

The American Cancer Society marks another year of success and progress tackling health disparities alongside Genentech. This important work continues in 2024 with a focus on piloting patient navigation programs in three key regions: Georgia, Ohio, and Oregon. These programs aim to accelerate community-based interventions that directly improve health equity and cancer outcomes.

Last year ACS received $4 million from Genentech to drive greater health equity and outcomes for all people with cancer with a goal of:

• Increasing access to innovative, high-quality cancer care and improving health equity for marginalized populations
• Expanding programmatic reach of patient navigation programs and seeking policy changes to enhance patient services to support the needs of every patient and family
• Addressing health-related psychosocial needs for every patient and their families
• Increasing access to, and utilization of biomarker testing and emerging therapies
• Increasing discoveries and diverse representation in clinical trials

For nearly 40 years, ACS and Genentech have collaborated in several efforts to advance cancer care for all patients. Genentech served as the founding sponsor of ACS’s Get Screened initiative, meant to rapidly restore and improve screening rates with a focus on communities that faced historical inequities and had the greatest impact from the pandemic.

Visit cancer.org/Genentech for more information.